Related Experiment Video
Updated: Oct 13, 2026

07:58
Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
RETRACTED: Mehenni et al. Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin
Lyes Mehenni1, Malika Lahiani-Skiba1, Guy Ladam2
1UFR of Health, Laboratory of Pharmaceutical & Biopharmaceutical Technology, Inserm U1239, UNIROUEN, Normandy University, 76183 Rouen CEDEX, France.
Pharmaceutics
|October 12, 2026
Abstract:
The journal retracts the article titled "Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin B" [...].
More Related Videos
Related Concept Videos
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

